Positron emission tomography in drug development and drug evaluation

被引:33
|
作者
Paans, AMJ [1 ]
Vaalburg, W [1 ]
机构
[1] Univ Groningen Hosp, PET Ctr, NL-9700 RB Groningen, Netherlands
关键词
D O I
10.2174/1381612003398906
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Positron Emission Tomography (PET) is an imaging modality which can determine biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labeled with positron emitting radionuclides as C-11, N-13, O-15 and F-18 and by measuring the annihilation radiation using a coincidence technique. This includes also measurement of the pharmacokinetics of labeled drugs and the assessment of the effects of drugs on metabolism. Because only very low amounts of the radiolabeled drug have to be administered, far below toxicity levels, human studies can be carried out even before the drug is entered in Phase I. Such studies can provide cost-effective predictive toxicology data and information on the metabolism and mode of action of drugs. PET is also very useful to study the metabolic consequences of gene expression or gene defects. In the last decade many genetically engineered small animal models have been developed. The study Of these animals with high resolution small animal PET cameras provides new opportunities in drug development. Especially valuable is the contribution of PET to bridge the gap between molecular biology, understanding of pathology and to the design of a new generation of drugs.
引用
收藏
页码:1583 / 1591
页数:9
相关论文
共 50 条
  • [1] Positron emission tomography: Applications in drug discovery and drug development
    Wang, JL
    Maurer, L
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (11) : 1053 - 1075
  • [2] Positron emission tomography in serotonergic drug development
    Andrée, B
    JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (01) : 90 - 91
  • [3] Positron emission tomography molecular imaging for drug development
    Matthews, Paul M.
    Rabiner, Eugenii A.
    Passchier, Jan
    Gunn, Roger N.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 175 - 186
  • [4] Use of positron emission tomography in anticancer drug development
    Aboagye, EO
    Price, PM
    INVESTIGATIONAL NEW DRUGS, 2003, 21 (02) : 169 - 181
  • [5] Positron emission tomography application to drug development and research
    Salvadori, Piero A.
    PHYSICS FOR MEDICAL IMAGING APPLICATIONS, 2007, 240 : 341 - 351
  • [6] Use of Positron Emission Tomography in Anticancer Drug Development
    Eric O. Aboagye
    Patricia M. Price
    Investigational New Drugs, 2003, 21 : 169 - 181
  • [7] Evaluation of drug effects with quantitative EEG and positron emission tomography
    Nagata, K
    Yokoyama, E
    Nara, M
    Hatazawa, J
    Kanno, I
    BRAIN TOPOGRAPHY TODAY, 1997, 1147 : 687 - 691
  • [8] Quantification in positron emission tomography for research in pharmacology and drug development
    Cunningham, VJ
    Gunn, RN
    Matthews, JC
    NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (07) : 643 - 646
  • [9] Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
    Miller, Jeffrey M.
    Kumar, Dileep
    Mann, J. John
    Parsey, Ramin V.
    CURRENT RADIOPHARMACEUTICALS, 2008, 1 (01) : 12 - 16
  • [10] Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
    Lamberts, Laetitia E.
    Williams, Simon P.
    van Scheltinga, Anton G. T. Terwisscha
    Lub-de Hooge, Marjolijn N.
    Schroeder, Carolien P.
    Gietema, Jourik A.
    Brouwers, Adrienne H.
    de Vries, Elisabeth G. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1491 - 1503